About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rifaximin in Patients With Diabetic Gastroparesis | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 2NCT04254549

Rifaximin in Patients With Diabetic Gastroparesis

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Lead sponsor: Mayo Clinic•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Mayo Clinic

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Men and women adult patients, aged 18-75, with diabetic gastroparesis
•Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; \> 20% remaining at 4 hours)

Exclusion Criteria

•Prior surgery to the stomach or esophagus
•Known mechanical obstruction of the GI tract
•Current or recent (\< 4 weeks) use of opioids
•Current/active use of cannabis
•Current or recent (\< 4 weeks) use of antibiotics
•Current or recent use of antifungal agents (\< 4 weeks)
•Prior treatment with rifaximin (\< 1 year)
•Uncontrolled diabetes with a HgbA1c \> 12
•Severe uncontrolled or untreated anxiety or depression.

Related studies

Early vs Delayed Surgery for Stricturing CD--a RCT

NCT05421455 · Crohn Disease

Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis

NCT07324785 · Diabetic Gastroparesis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394 · Inflammatory Bowel Disease (IBD), Crohn Disease (CD), and more

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420 · IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, and more

Immunological Characteristics of Preclinical IBD

NCT05698745 · Crohn Disease, Ulcerative Colitis, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 3, 2025Terms

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment5

Start dateJun 2019

Last updatedNov 3, 2025

Condition

Crohn Disease Diabetic Gastroparesis

Locations shown

Mayo Clinic in Florida

Jacksonville, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 3, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions